Scientific article

Adapting Preclinical Benchmarks for First-in-Human Trials of Human Embryonic Stem Cell-Based Therapies

Published inStem cells translational medicine, vol. 5, no. 8, p. 1058-1066
Publication date2016

: As research on human embryonic stem cell (hESC)-based therapies is moving from the laboratory to the clinic, there is an urgent need to assess when it can be ethically justified to make the step from preclinical studies to the first protocols involving human subjects. We examined existing regulatory frameworks stating preclinical requirements relevant to the move to first-in-human (FIH) trials and assessed how they may be applied in the context of hESC-based interventions to best protect research participants. Our findings show that some preclinical benchmarks require rethinking (i.e., identity, purity), while others need to be specified (i.e., potency, viability), owing to the distinctive dynamic heterogeneity of hESC-based products, which increases uncertainty and persistence of safety risks and allows for limited predictions of effects in vivo. Rethinking or adaptation of how to apply preclinical benchmarks in specific cases will be required repeatedly for different hESC-based products. This process would benefit from mutual learning if researchers included these components in the description of their methods in publications.

Citation (ISO format)
BARAZZETTI, Gaia, HURST, Samia, MAURON, Alex. Adapting Preclinical Benchmarks for First-in-Human Trials of Human Embryonic Stem Cell-Based Therapies. In: Stem cells translational medicine, 2016, vol. 5, n° 8, p. 1058–1066. doi: 10.5966/sctm.2015-0222
Main files (1)
Article (Published version)
ISSN of the journal2157-6564

Technical informations

Creation09/07/2016 4:00:00 PM
First validation09/07/2016 4:00:00 PM
Update time03/15/2023 12:42:48 AM
Status update03/15/2023 12:42:48 AM
Last indexation05/02/2024 5:44:37 PM
All rights reserved by Archive ouverte UNIGE and the University of GenevaunigeBlack